priors.science/reviews/cardiac-amyloidosis

Cardiac Amyloidosis

The current evidence on 19 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

19claims tracked
176primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 7 Likely · 8 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableDaratumumab plus bortezomib, cyclophosphamide and dexamethasone improves light-chain amyloidosis responseAL TreatmentEstablished92%15
StableNational Amyloidosis Centre staging stratifies transthyretin amyloid cardiomyopathy prognosisStaging PrognosisEstablished90%8
StableTechnetium pyrophosphate scintigraphy diagnoses transthyretin amyloid cardiomyopathyDiagnosisEstablished88%4
StableTafamidis reduces mortality in transthyretin amyloid cardiomyopathyTTR StabilisersEstablished86%10
StableVutrisiran reduces mortality in transthyretin amyloid cardiomyopathyTTR SilencingLikely82%7
StableAcoramidis reduces mortality in transthyretin amyloid cardiomyopathyTTR StabilisersLikely82%13
StableHaematologic response depth predicts light-chain amyloidosis survivalAL TreatmentLikely72%6
StableTafamidis efficacy in wild-type and variant transthyretin amyloidosisTTR StabilisersLikely71%7
StableCRISPR TTR editing reduces serum TTR by 90%Emerging TherapiesLikely70%3
StableNT-proBNP predicts transthyretin amyloid cardiomyopathy mortalityStaging PrognosisLikely70%15
StableEarly tafamidis initiation gives superior survivalTTR StabilisersLikely70%10
StableV142I transthyretin amyloid cardiomyopathy has worse prognosisStaging PrognosisUncertain64%5
StablePatisiran preserves function in transthyretin cardiac amyloidosisTTR SilencingUncertain58%15
StableTTR silencing reduces serum TTR over 80%TTR SilencingUncertain55%15
StableTransthyretin amyloidosis therapy and transcatheter aortic valve replacement improve aortic stenosis outcomeHF ManagementUncertain53%6
StableTransthyretin amyloid cardiomyopathy underdiagnosed in heart failure with preserved ejection fractionDiagnosisUncertain52%6
StableTafamidis preserves left ventricular mass and functionTTR StabilisersUncertain52%8
StableMineralocorticoid receptor antagonist use reduces mortality in transthyretin amyloid cardiomyopathyHF ManagementUncertain48%4
StableEplontersen reduces TTR in transthyretin amyloid cardiomyopathyEmerging TherapiesUncertain47%3
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic